冠脉介入治疗围术期应用磺达肝癸钠或依诺肝素的临床结局  

Clinical outcomes of fondaparinux versus enoxaparin during percutaneous coronary intervention perioperation

作　　者：黄兆辉[1] 夏皓[1] 刘东凤 刘昌松[1] 苏双[1] 吴赛珠[1] 

机构地区：[1]南方医科大学南方医院,广东广州510515

出　　处：《中国老年学杂志》2016年第9期2086-2087,共2页Chinese Journal of Gerontology

基　　金：国家"973"项目子课题(2007CB507404);广东省科技计划项目(2010B031500013)

摘　　要：目的比较冠脉介入治疗（PCI）围术期应用磺达肝癸钠与依诺肝素的安全性和有效性。方法对2015年1~6月于南方医院行冠脉介入治疗的患者进行随机对照分析,患者围术期间皮下注射磺达肝癸钠（磺达肝癸钠组）或依诺肝素（依诺肝素组）,进行3~5 d抗凝治疗。对两组患者术后并发症进行比较分析,对患者进行3个月终点事件的电话随访。结果磺达肝癸钠相比于依诺肝素抗凝能够降低48 h内出血事件（P=0.027）,同时不增加缺血事件,两组3个月随访无统计学差异意义（P〉0.05）。结论 PCI围术期应用磺达肝癸钠和依诺肝素的疗效和安全性相似。Objective To compare the safety and efficacy of fondaparinux with enoxaparin during percutaneous coronary intervention（ PCI） perioperaion. Methods The patients were given subcutaneous injection of either fondaparinux or enoxaparin as a 3 ~ 5 days＇ anticoagulant therapy during perioperation. Anticoagulant-related complications,identified and classified as thromboembolic and bleeding events,were compared between the two groups and patients were followed up in 3 months. Results Use of fondaparinux reduced the post-PCI bleeding events in 48 hours than use of enoxaparin without increasing ischemic events（ P = 0. 027）. Conclusions Fondaparinux is no less than enoxaparin in perioperative anticoagulation of percutaneous coronary intervention.

关 键 词：冠脉介入 围术期 磺达肝癸钠 依诺肝素 

分 类 号：R544.1[医药卫生—心血管疾病]